{
  "id": 9131816,
  "title": "Why is Viking Therapeutics stock surging today?",
  "url": "https://urgent.news/2026/09/22/why-is-viking-therapeutics-stock-surging-today",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-22T11:19:26.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/stock-market-news/why-is-viking-therapeutics-stock-surging-today-93CH-4910491"
  },
  "original_language": "en",
  "account": "Viking Therapeutics' shares jumped 39.5% in pre-market trading following the release of impressive top-line results from its VK2735 maintenance study. The San Diego-based biopharmaceutical company showcased compelling data that addressed a major question in the GLP-1/GIP receptor agonist space: can patients maintain weight loss with reduced dosing frequencies?\n\nIn the 12-week maintenance phase, every-other-week dosing managed to preserve up to 97% of prior weight loss, while monthly dosing yielded up to 90% retention, compared to only 61% for placebo. This data provided strong evidence that VK2735 could potentially establish adherence as a new competitive battleground in obesity and chronic metabolic disease.\n\nThe encouraging safety profile of VK2735, with GI-related adverse events comparable to placebo, further bolstered investor confidence. The company plans to explore oral maintenance dosing regimens in a future part 2 of the study. Viking stock had already been on an upward trajectory ahead of the data release, with Oppenheimer maintaining an Outperform rating and a $100 price target. The positive news was driven entirely by company-specific results and not influenced by broader market trends.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}